Best Biotech Stocks To Invest In Right Now


I really like Moderna (NASDAQ:MRNA). The company’s COVID-19 vaccine has been instrumental in preventing infections, hospitalizations, and (most importantly) deaths. Its messenger RNA (mRNA) platform could be used to develop vaccines and therapies targeting a wide range of diseases. I’m not surprised that Moderna ranked No. 3 on the Axios-Harris annual survey of corporate reputations and was the top healthcare company on the list.

But it’s possible to like a company, yet not be a fan of its stock. Moderna was a great stock to buy in 2020 and even earlier this year. However, the stock is now trading at a sky-high valuation.

I don’t think Moderna’s current market cap of $180 billion-plus is justified at this point. Here are two biotech stocks that are better buys right now than Moderna. 

Image source: Getty Images.

Best Biotech Stocks To Invest In Right Now: Payment Data Systems, Inc.(PYDS)


Payment Data Systems, Inc. was founded in July 1998 and incorporated in the State of Nevada. We are an integrated payment solutions provider offering a range of customized services to merchants, billers, banks, service bureaus, and card issuers. We operate solely in the U.S. through our two operating entities, Payment Data Systems, Inc. and FiCentive, Inc., our primary business is processing electronic payments for other companies including all types of Automated Clearing House (“ACH”) processing, credit, prepaid card and debit card-based processing. In our 17-year history, we have created a loyal customer base that rely on us for our convenient, secure, innovative and adaptive services and technology, and we have built long-standing and valuable relationships with premier banking institutions such as Fifth-Third Bank, Sunrise Bank, and Wells Fargo.


Payment Data Systems, Inc.   Advisors’ Opinion:

  • [By Ethan Ryder]

    Payment Data Systems, Inc. (NASDAQ:PYDS) shares were down 5.8% on Thursday . The stock traded as low as $2.85 and last traded at $3.39. Approximately 519,455 shares were traded during trading, an increase of 268% from the average daily volume of 141,225 shares. The stock had previously closed at $3.60.

  • [By Ethan Ryder]

    Euronet Worldwide (NASDAQ: EEFT) and Payment Data Systems (NASDAQ:PYDS) are both finance companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

  • [By Joseph Griffin]

    Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:

    Get Payment Data Systems alerts:

    Euronet Worldwide (EEFT) versus Payment Data Systems (PYDS) Financial Comparison (americanbankingnews.com) Payment Data Systems (PYDS) Issues Quarterly Earnings Results, Beats Estimates By $0.06 EPS (americanbankingnews.com) Payment Data Systems’ (PYDS) CEO Louis Hoch Q1 2018 Results – Earnings Call Transcript (seekingalpha.com) Edited Transcript of PYDS earnings conference call or presentation 15-May-18 9:00pm GMT (finance.yahoo.com) Payment Data Systems Announces Results for the First Quarter of 2018 (finance.yahoo.com)


    NASDAQ:PYDS traded up $0.03 on Friday, reaching $1.75. 66,441 shares of the stock traded hands, compared to its average volume of 170,972. Payment Data Systems has a 12 month low of $1.17 and a 12 month high of $4.10.

  • [By Logan Wallace]

    Net 1 UEPS Technologies (NASDAQ: UEPS) and Payment Data Systems (NASDAQ:PYDS) are both small-cap industrial products companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Best Biotech Stocks To Invest In Right Now: Sapiens International Corporation N.V.(SPNS)


Sapiens International Corporation N.V. provides software solutions for the insurance industry primarily in North America, Europe, Israel, and the Asia Pacific. The company offers solutions for the property and casualty (P&C)/general insurance, as well as life, pension, and annuity markets. Its products include RapidSure, a component-based software solution used for general, personal, and commercial lines of businesses, including homeowners, fleet insurance, and specialty lines insurance products; IDIT, a component based software solution that addresses the needs of general insurance carriers for traditional insurance, direct insurance, banc assurance, and brokers markets; Insight for Reinsurance, a solution to handle P&C/general reinsurance activities of general insurance carriers and brokers; and Insight for P&C, a software solution for P&C carriers to support legacy solutions. The company?s products also comprise ALIS, a software solution for individual, group, and work site life and pension insurance products; eMerge, a rules-based model-driven architecture that enables the creation of enterprise applications with little or no coding using agile methodologies; and Decision, a business decision management solution developed for the financial services market, including mortgage banks, investment banks, and insurers. In addition, it provides implementation and integration services; custom-made IT solutions that assists organizations to meet its business challenges; and legacy modernization solution, mobile application solution, and application delivery services. Sapiens International Corporation sells its products and services through various distribution channels, which include direct sales force, system integrators, and distributors. The company was founded in 1982 and is headquartered in Rehovot, Israel. As of January 27, 2012, Sapiens International Corp. NV operates as a subsidiary of Formula Systems (1985) Ltd.


Advisors’ Opinion:

  • [By Joseph Griffin]

    Sapiens International Co. (NASDAQ:SPNS) shares hit a new 52-week high on Thursday . The company traded as high as $14.50 and last traded at $14.42, with a volume of 3541 shares traded. The stock had previously closed at $13.94.

  • [By Stephan Byrd]

    Sapiens International Co. (NASDAQ:SPNS) declared a … dividend on Friday, September 21st, Wall Street Journal reports. Stockholders of record on Tuesday, October 16th will be paid a dividend of 0.2337 per share by the technology company on Tuesday, October 30th. The ex-dividend date of this dividend is Monday, October 15th.

Best Biotech Stocks To Invest In Right Now: 360 DigiTech, Inc.(QFIN)


360 DigiTech, Inc., through its subsidiaries, operates a digital consumer finance platform under the 360 Jietiao brand in the People's Republic of China. Its platform provides online consumer finance products to the borrowers funded by institutional funding partners. The company also provides incremental credit assessment, collection, and other services, as well as guarantee for defaulted loans. The company was formerly known as 360 Finance, Inc. and changed its name to 360 DigiTech, Inc. in September 2020. 360 DigiTech, Inc. was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.


Advisors’ Opinion:

  • [By Keith Noonan (TMFNoons)]

    After a battering of sell-offs driven by regulatory concerns over the past month, investors are suddenly showing an increased appetite for beaten-down Chinese tech names. Bilibili (NASDAQ:BILI), Full Truck Alliance (NYSE:YMM), KE Holdings (NYSE:BEKE), 360 DigiTech (NASDAQ:QFIN), Tencent Music Entertainment Group, and Vipshop Holdings all managed to post double-digit stock rallies in Tuesday’s trading.

  • [By Max Byerly]

    360 Finance (NASDAQ:QFIN) and Synchrony Financial (NYSE:SYF) are both computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

  • [By Logan Wallace]

    360 Finance (NASDAQ:QFIN) and Yirendai (NYSE:YRD) are both small-cap computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.

Leave a Reply

Your email address will not be published.